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Available online 29 May 2012Abstract Bone marrowmesenchymal stem cells (MSC) have been tested and proven effective in some neurodegenerative diseases,
but their tracking after transplantationmay be challenging. Our group has previously demonstrated the feasibility and biosafety of rat
MSC labeling with iron oxide superparamagnetic nanoparticles (SPION). In this study, we investigated the therapeutic potential of
SPION-labeled MSC in a rat model of Huntington's disease, a genetic degenerative disease with characteristic deletion of striatal
GABAergic neurons. MSC labeled with SPION were injected into the striatum 1 h after quinolinic acid injection. FJ-C analysis
demonstrated that MSC transplantation significantly decreased the number of degenerating neurons in the damaged striatum 7 days
after lesion. In this period, MSC transplantation enhanced the striatal expression of FGF-2 but did not affect subventricular zone
proliferation, as demonstrated by Ki67 proliferation assay. In addition, MSC transplantation significantly reduced the ventriculomegaly
in the lesioned brain. MRI and histological techniques detected the presence of the SPION-labeled cells at the lesion site.
SPION-labeled MSC producedmagnetic resonance imaging (MRI) signals that were visible for at least 60 days after transplantation. Our
data highlight the potential of adult MSC to reduce brain damage under neurodegenerative diseases and indicate the use of
nanoparticles in cell tracking, supporting their potential as valuable tools for cell therapy.
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Huntington's disease (HD) is a progressive, fatal and
neurodegenerative disorder produced by CAG trinucleotide
expansion in exon 1 of the gene coding for the huntingtin
protein (htt) (The Huntington's Disease Collaborative
Research Group, 1993). Despite the widespread expression
of htt in the brain and the body, expression of mutant htt
leads to the selective death of the medium-size spiny
GABAergic neurons in the striatum (Cowan and Raymond,
2006; Sieradzan and Mann, 2001; Subramaniam et al., 2009),
resulting in the appearance of generalized involuntary
movements. Excitotoxicity is suggested to be involved in
the pathogenesis of HD and intrastriatal injection of
quinolinic acid (QUIN), an agonist of the N-methyl-D-
aspartic acid receptor, induces a similar pattern of
neuronal death (Estrada Sanchez et al., 2008).
MSC transplantation has been found to produce im-
provements in several disease neurodegenerative models,
including Alzheimer's disease (Lee et al., 2010), amyo-
trophic lateral sclerosis (Kassis et al., 2008) and acid
sphingomyelinase deficiency (Jin et al., 2002). MSC-
mediated neuroprotection is often associated with their
anti-inflammatory effects (Ohtaki et al., 2008) and/or
secretion of growth factors (Caplan and Dennis, 2006),
which might serve to inhibit disease progression (Le Blanc
and Ringden, 2007; Uccelli et al., 2007). The neuropro-
tective properties of MSC raise the possibility of develop-
ing a therapy to prevent or retard the degeneration of
vulnerable striatal neuronal populations in HD, which
could be a more feasible approach than neuronal replace-
ment in a clinical scenario.
The increasing number of studies focusing on regener-
ative medicine and stem cell transplantation is being
accompanied by the development of techniques using
many types of nanoparticles. The combination of nano-
technology with stem cell research may be able to address
some challenges in this research field, including stem cell
monitoring after transplantation. Since most experimen-
tal cell-tracking techniques require histological analysis,
non-invasive approaches to assess migration, fate and
integration of transplanted cells represent a significant
advance for the clinical application of biomedical treat-
ments using stem cells. MRI of magnetically labeled cells is
an emerging technology that offers excellent resolution in
vivo. SPION are negative contrast agents that render
transplanted stem cells trackable when imaged with the
appropriate pulse sequence. These nanoparticles consist
of magnetite (iron oxide) cores, which are coated with
dextran or siloxanes encapsulated by a polymer or further
modified to facilitate internalization (Jung and Jacobs,
1995; Rogers et al., 2006).
Our group has recently shown that SPION-labeling does
not affect viability, proliferation and differentiation of MSC
(Jasmin et al., 2010) and we have now applied the same
technique to track MSC in vivo in a rat model of Huntington's
disease. Moreover, to investigate the neuroprotective
potential of MSC in HD it is important to evaluate the effect
before massive cell death. In this report, we implanted
SPION-labeled MSC into the striata of rats 1 h after QUIN
injection, to investigate their neuroprotective effects and to
monitor their fate over the long term.Methods
Cell culture
To obtain bone marrow cells, tibias and femurs were isolated
from Wistar rats, the epiphyses were removed, and the
bones were individually inserted in 1 mL automatic pipette
polypropylene tips and then placed in 15 mL tubes. The
bones were centrifuged at 300×g for 1 min and the pellets
suspended in Dulbecco's modified Eagle's medium F-12 (DMEM
F-12; Invitrogen Inc., Carlsbad, CA, USA), supplemented with
10% fetal bovine serum (FBS; Invitrogen Inc.), 2 mM L-glutamine
(Invitrogen Inc.), 100 U/mL penicillin (Sigma-Aldrich Co., St.
Louis, MO, USA), and 100 μg/mL streptomycin (Sigma-Aldrich
Co.). Mononuclear cells were purified by centrifugation in
Histopaque 1083 (Sigma-Aldrich Co.) gradient at 400×g for
30 min. After three washes in phosphate-buffered saline
(PBS) using centrifugation at 300×g, the cells were plated in
75 cm2 flasks with supplemented DMEM F-12 andmaintained
in 5% CO2 atmosphere at 37 °C. The medium was replaced
48–72 h after initiation of the culture, to remove nonadherent
cells, and the adherent cells were grown to confluence before
each passage. The medium was replaced three times a week.
After a third replating, cultured cells were labeled with
SPION.Labeling and viability of MSC
As described previously (Arbab et al., 2004a, 2004b; Jasmin
et al., 2010), a stock solution of protamine chlorhydrate
(Valeant Pharmaceuticals International, São Paulo, SP,
Brazil) (5 μg/mL) was added to the culture medium at a
dilution of 1:1000 and mixed with SPION (Feridex IV,
Advanced Magnetics Inc., Cambridge, MA, USA) (100 μg/
mL) for 30 min at room temperature on a rotating shaker.
This solution containing FE–Pro complexes was added to
an equal volume of the culture medium, such that the
final concentration of ferumoxides was 50 μg/mL and
the final dilution of protamine sulfate was 1:2000. The
cell cultures were kept at 37 °C for 4 h in this medium,
washed in phosphate-buffered saline (PBS, pH 7.4) tryp-
sinized and transplanted or fixed with 4% paraformal-
dehyde (PF) for in vitro assays. For viability assays, cells
were washed and incubated for 30 min at room temper-
ature with the LIVE/DEAD viability/cytotoxicity kit (Invitro-
gen Inc.). Due to intracellular esterase activity determined
by the enzymatic conversion of cell-permeant calcein to the
intensely fluorescent calcein, green fluorescence depicts
live cells. Dead MSC show red fluorescence induced by
ethidium homodimer, which enters cells with damaged
membranes.Prussian blue staining
For Prussian blue staining, which indicates the presence of
iron, cells or mounted sections were washed and incubated
for 20 min in 10% potassium ferrocyanide (VETEC) and 20%
hydrochloric acid (VETEC). After washing, samples were
counterstained with nuclear fast red (VETEC).
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For electron microscopy, mesenchymal cells were washed in
0.1 M phosphate buffer, pH 7.2, and then fixed with 2%
glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate
buffer for 1 h at room temperature. Cells were scrubbed off
the bottles with a rubber cell scraper, after being washed
three times in PB, and the suspension centrifuged at 250×g
for 5 min each time. The pellet was then washed twice in
0.1 M cacodylate buffer, pH 7.2 and post-fixed in a solution
containing 1% osmium tetroxide and 0.8% potassium ferrocy-
anide and 5 mM CaCl2 in 0.1 M cacodylate buffer, pH 7.2 for
60 min at room temperature and in the dark. Pellets were cut
into small (1–3 mm3) pieces, dehydrated in acetone, and
embedded in Epoxy resin. Thin sections were stained with
uranyl acetate for 40 min and lead citrate for 5 min, and
observed in a JEOL 1200 microscope operating at 80 kV.
Surgery and Transplantation procedures
Surgeries were performed on 3-month-old male Wistar rats,
weighing 300 to 350 g. All experiments were conducted in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (NIH Publication No.
80‐23), and were approved by the Committee for the Use of
Experimental Animals of our Institution. Rats were immobi-
lized under ketamine hydrochloride (50 mg/kg, i.p.) and
xylazine hydrochloride (10 mg/kg, i.p.) anesthesia and
injected bilaterally with 1 μL QUIN 100 nM into the striata
at the following stereotaxic coordinates: A/P 0.7, M/L −3.0
and D/V −5.0 mm from bregma. After 1 h, cell transplants
(5×105 or 1×106 in 7 μL saline) were made using the same
coordinates. Accordingly, the control striata were injected
with 7 μL saline. At different time point post-surgery, the
rats inhaled a lethal dose of ether and were perfused
transcardially with 0.9% saline, followed by a buffered 4% PF
solution, and 10% sucrose in PF. The removed brains were
immersed in a 30% buffered sucrose solution overnight for
cryoprotection, then quickly frozen in liquid nitrogen and
cut coronally on a cryostat at 20 μm thickness.
In vivo MRI
Magnetic resonance images were acquired at 1.5-T (Magnetom
Avanto, Siemens Medical, Erlangen, Germany) using an
8-channel knee coil. The study protocol consisted of high-
resolution T2 weighted sequences in the coronal plane
[repetition time (TR) 4000 ms, echo time (TE) 83 ms, matrix
256×112, section thickness 2 mm, NEX 9] and T2* weighted
sequences in the sagittal plane (TR 11 ms, TE 4.8 ms, matrix
384×156, section thickness 0.7 mm, NEX 3).
Immunohistochemistry
For immunofluorescence staining, the sections were pre-
incubated for 30 min, at room temperature, in a solution
containing 10% normal goat serum (Sigma-Aldrich) to block
nonspecific binding sites. Sections were then incubated
overnight with the primary antibodies in PBS, at 4 °C. The
following primary antibodies were used: mouse monoclonal
IgG anti-dextran (1:1000, StemCell Technologies, Vancouver,BC) and rabbit monoclonal IgG anti-Ki67 (1:100, Abcam,
Cambridge, MA). The secondary antibodies used were, respec-
tively, Alexa 488-conjugated goat anti-mouse IgG (1:1000,
Invitrogen) and Cy3-conjugated goat anti-rabbit IgG (1:400,
Jackson ImmunoResearch, West Grove, PA). Sections were
incubated in the secondary antibodies for 2 h at 37 °C. After
rinsing in PBS, the sections were kept for 15 min in a nuclear
staining solution with 0.1% DAPI (4,6-diamidino-2-phenylin-
dole, Sigma-Aldrich) and mounted using N-propylgalate
mounting medium. Images were acquired using a Zeiss
Axiovert 200 M microscope equipped with an Apotome slide
and fluorescence optics or a Zeiss LSM 510 META confocal
microscope.
FJ-C Staining
FJ-C (Histo-Chem Inc., Jefferson, AR, USA), a specific
marker of neuronal death [28, 29] was used to evaluate the
extent of neurodegeneration after QUIN injection. Sections
were dehydrated in 100% ethanol for 3 min, followed by
1 min in 70% ethanol. After 1 min wash in distilled water, the
sections were treated with 0.06% KMnO4 with gentle
agitation for 15 min. After washing in distilled water, the
sections were placed in a solution composed of 0.001% FJ-C
in 0.1% acetic acid for 30 min. The slides were washed three
times with distilled water, dried, and coverslipped with DPX
mounting medium (Electron Microscopy Sciences, Fort
Washington, PA, USA).
Cell counting and ventricular area measurements
FJ-C staining was performed in the lesion core. We counted
all FJ-C-positive cells (n=7) in 6 predetermined striatal
fields, which included a representative area of the lesion.
Coronal sections of the SVZ were chosen along the rostro-
caudal axis (+1.00 mm to +0.20 mm from the bregma) using
the same anatomical references for both groups, including:
olfactory bulb, cortex, corpus callosum, and white matter.
In 6 to 8 sections, all immunoreactive cells in the SVZ of the
lateral wall of lateral ventricles were counted (except for
the dorsolateral SVZ, to exclude migrating cells) including a
distance of 60 μm from the ventricular lumen (n=8). The
lateral walls were measured using AxioVision software and
the values were plotted as the average number of cells/mm
±SEM for each group. To assess ventricular size (n=4), serial
coronal sections at different rostrocaudal levels of the brain
were photographed, and the border of each ventricle was
outlined using AxioVision software. We measured the ventric-
ular area in three rostrocaudal levels: anterior (2.7–1.6 mm
distant from the bregma), medial (1.0–0.7 mm distant from
the bregma), and posterior (0.26–0.4 mm distant from the
bregma).
Immunoblotting assay
Animals (n=4) were killed and the striata were carefully
dissected in ice-cold 10 mM PBS. Tissues were homogenized
in ice-cold lysis buffer (20 mM Tris–HCl pH 7.4; 150 mM NaCl;
2 mM EDTA; 0.2% Triton X-100; 1:1000 of Protease Inhibitor
Cocktail Set III [Calbiochem]). Following incubation on ice
for 40 min, the lysed cells were centrifuged at 12,000×g for
Figure 2 Uptake of SPION in cultured MSC. Micrographs showing anti-dextran staining in labeled MSC (B) but not in control non-
labeled MSC (A). SPION appear blue within the MSC cytoplasm after Prussian blue staining (C). Analysis of cellular viability conducted
with LIVE/DEAD kit (D–F) in samples of SPION-labeled (E) and non-labeled MSC (D). Graph shows results of live and dead cell
quantifications (F). Cell viability was similar in both groups. Transmission electron microscopy evidenced the presence of numerous
iron-containing vesicles (arrows) in the cytoplasm of MSC (G) (*pb0.05, Student's t-test). Scale bars: 20 μm. Scale bars: A, B, D and
E=20 μm; C=10 μm; G=200 nm.
Figure 1 Characteristic feature of a striatal neurotoxic lesion in the striatum after QUIN injection. FJ-C positive cells were
detected at day 1 after QUIN striatal injection (B), but not in the striatum injected with saline (A). Graph shows the quantification of
FJ-C positive cells in striata (C). Neurodegeneration was observed from day 1 to day 7 post-injection, and staining at different time
points after QUIN injection was significantly higher at 1–3 d (*pb0.05, one-way ANOVA followed by Tukey's test). Scale bar: A and
B=20 μm.
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concentration was determined using the Qubit-kit protein
(Invitrogen) and 40 μg of total protein was loaded in 10%
SDS-PAGE and transferred onto 0.2-μm nitrocellulose mem-
branes (Amersham Biosciences, Pittsburgh, PA, USA). Mem-
branes were blocked with 0.05% Tween-20 in PBS (PBS-T)
containing 5% nonfat milk, for 1 h. After washing for 15 min in
PBS-T, themembranes were incubated overnight with primary
antibody in PBS-T at 4 °C with continuous shaking. Primary
antibodies were directed against fibroblast growth factor-2
(FGF-2, 1:2000, Millipore) and α-tubulin (1:10,000, Sigma-C
A
Figure 3 In vivo MR imaging. T2*-weighted images of a rat injecte
of the injected SPION-labeled MSC confirmed the cell labeling (A). O
injected area, indicating the accumulation of labeled MSC within the
sagittal C and horizontal D planes) but not in the lesioned and untre
injection site. Scale bar: A=20 μm.Aldrich). After washing, the membranes were incubated at
room temperature for 1 h with secondary horseradish perox-
idase conjugated anti-mouse antibody (1:5000; Sigma) in PBS-
T. The complex was revealed by chemiluminescence luminol
reagent—ECL kit (Amersham Biosciences) and exposed to
hyper film (Amersham Biosciences) for 30 min for FGF-2 and
5 min for α-tubulin. Scanning densitometry was employed to
determine the relative intensity of the signal produced by
protein expression levels and analyzed using Image J software
(NIH). Loading controls were performedwith an anti-α-tubulin
antibody.B
D
d with SPION-labeled MSC. Anti-dextran staining using an aliquot
ne hour after injection, a noticeable darkening appeared in the
lesioned and transplanted hemisphere (arrows in the coronal B,
ated hemisphere. The signal remained primarily localized at the
Figure 4 Long-term monitoring of SPION-labeled MSC. Coro-
nal T2*-weighted images at different time points after delivery
of SPION-labeled MSC. Hypointense signals (black spots) indi-
cated the presence of the cells in all analyzed periods, and the
signal was gradually reduced until 60 days after lesion (DAL).
Seven days after cell injection, the black spots were also
observed in the contralateral lesioned and non-transplanted
striatum, and persisted for at least 60 DAL.
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Statistical analysis was performed by one-way ANOVA and the
Tukey'smultiple comparison post hoc test. Student's t-test was
applied when indicated in the text (Graph Pad Prism 4
software). Pb0.05 was considered as statistically significant.
Results
Neurodegeneration after QUIN
To define the therapeutic window after QUIN injections, we
examined the chronology of cellular death after QUIN
injections, using Fluoro-Jade C (FJ-C) as a tool for staining
degenerating neurons. Striatal neurodegeneration was ob-
served after the neurotoxic lesion (Figure 1B), and FJ-C
positive cells were detected from day 1 to day 7 post-
injection. Positive FJ-C staining was increased at earlier
time points (1–3 d) following QUIN injection (Figure 1C).
Because QUIN is an acute lesion, we considered that MSC
transplantation immediately after lesion would provide a
better effect.
In vitro characterization of SPION-labeled MSC
Studies from our group (Jasmin et al., 2010) and others have
shown that labeling with SPION is feasible without affecting
cell viability, proliferation, and differentiation ability (Arbab
et al., 2004a, 2004b; Yang et al., 2011). The following
experiments were designed to further investigate the SPION
labeling. FITC-anti-dextran and Prussian blue showed intense
staining of MSC, and confirmed the SPION uptake by these cells
(Figures 2A–C). According to the live/dead assays, the number
of surviving SPION-labeled MSC was similar to non-labeled MSC
(Figures 2D–F). Thus, the next experiments were carried out
with viable SPION-labeled MSC. Electron microscopy demon-
strated that virtually all SPION particles were located inside the
cells (Figure 2G). High-efficiency intracellular magnetic label-
ing would prevent loss of the label after MSC implantation.
In vivo tracking of SPION-labeled MSC
The next experiments were carried out to validate SPION-
labeled MSC as a potential tool for MRI tracking. A rat
received two bilateral striatal QUIN injections, followed by
unilateral striatal injection of 106 SPION-labeled MSC and
the contralateral striatum was injected with an equivalent
volume of saline to exclude the possibility that bleeding
after surgery could result in MRI signal changes and Prussian
blue positive staining. One hour after transplantation,
labeled MSC produced a visible and local hypointense MRI
signal, while the contralateral lesioned striatum did not
show signal alteration (Figure 3). This data indicated that
internalized SPION induced sufficient cell MRI contrast to
allow in vivo tracking of transplanted MSC. The MRI signal
was visible at 1, 7, 14, 28, 42 and 60 days after implantation
into the QUIN-lesioned striatum (Figure 4). Moreover, at day
7, a hypointense MRI signal was also found in the contralat-
eral lesioned but not transplanted striatum (Figure 4).
Histological evaluation with Prussian blue 60 days aftertransplantation also revealed the presence of iron in the
striata of both hemispheres (Figure 5), supporting the MRI
data. Most labeled cells were located next to blood vessels and
lateral ventricles in both hemispheres. It is possible that cells
attracted by inflammatory cytokines migrated from the
injected to the contralateral hemisphere through the blood
flow and/or the liquor. Brains injected with unlabeled MSC or
the supernatant of SPION-labeled MSC after washing showed
no MRI signal or Prussian blue staining (data not shown).
Neuroprotective effect of MSC transplantation
Analysis of neurodegeneration revealed significant reduction
of FJ-C positive neurons in striata that received MSC trans-
plants (pb0.05). Striatal neurodegeneration was significantly
reduced at day 7 after MSC delivery, but this effect was not
observed at day 1 (Figure 6).
Increased cell proliferation in the subventricular zone
(SVZ) could constitute an alternative effect of MSC trans-
plantation. To investigate the pattern of cell proliferation in






Figure 5 Prussian blue staining in the brain. Blue spots within both lesioned and transplanted (A and A′) and non-transplanted
striatum (B, B′ and B″) showing the presence of SPION. Tissue counterstained with nuclear fast red. Magnification of the slides
indicates the presence of SPION-labeled cells. Scale bar: A′, B′ and C′ 40 μm.
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no differences between rats transplanted with MSC and the
saline control group at 7 days after injury. However, both
groups showed increased numbers of Ki-67+ cells compared
to unlesioned rats (Figure 7). This observation is in
accordance with previous observations of cell proliferation
enhancement in the SVZ ipsilateral to the QUIN lesioned
striatum (Curtis et al., 2003; Tattersfield et al., 2004) and
increased cell proliferation in the HD human brain (Curtis
et al., 2003; Tattersfield et al., 2004).
Ventriculomegaly is one of the most prominent features of
the progressive neurodegeneration in HD patients and in the
QUIN model (Guncova et al., 2011). To investigate if MSC
transplantation produced long-term effects in our model, we
measured the degree of ventriculomegaly, which is an
indication of striatal shrinkage. Nine months after transplan-
tation, there was a significant enlargement of the ventricles in
QUIN-saline rats compared to unlesioned rats. However,
MSC treatment significantly decreased the enlargement of
the ventricles (Figure 8). This effect was more evident and
significant in the medial region, next to the MSC injection
site (pb0.05). The significant reduction in ventriculomegaly
9 months after transplantation suggests that MSC transplan-
tation can generate long-term positive effects after injury.
Increased levels of FGF-2 after MSC transplantation
We next investigated whether the effect of MSC on striatal
cell survival at day 7 was associated with enhanced
expression of fibroblast growth factor 2 (FGF-2). Immuno-
blotting analysis revealed that striatal FGF-2 expression is
significantly reduced after QUIN injection, compared to
unlesioned animals (pb0.05). On the other hand, MSCtransplantation after QUIN injection can reverse this effect,
since QUIN-MSC rats showed levels of striatal FGF-2 similar
to those of unlesioned animals (Figure 9). Because brain-
derived neurotrophic factor (BDNF) is believed to be an
important regulator of neuronal survival in the striatum, we
also analyzed its expression, and found no significant
differences between the groups (Figure 9).
Discussion
MSC are known to play a therapeutic role in brain lesions,
and can be safely cultured in vitro with no risk of malignant
transformation (Bernardo et al., 2007; Uccelli et al., 2008).
This is the first time that a therapeutic effect of MSC in HD with
transplantation 1 h after QUIN lesions, and using a specific
neurodegenerative marker, has been shown. We demonstrated
that local MSC delivery has neuroprotective effects in a rat
model of HD, leading to reduced striatal neurodegeneration
and decreasing ventriculomegaly after QUIN injection. Fur-
thermore, we demonstrated the feasibility of SPION labeling,
and cells loaded with SPION were monitored in vivo in the
striata of QUIN-lesioned rats.
We used FJ-C to evaluate the chronology of cellular death
in the QUIN model and the effects of MSC on neurodegenera-
tion. FJ-C is a good marker of degenerating neurons, and
stains all types of cell death. Previous findings have
indicated a peak at the third day, with reduced staining on
the fifth day after lesion, using Transferase Biotin-dUTP Nick
End Labeling (TUNEL) (Bordelon et al., 1999). We found a
peak of FJ-C cells from 1 to 3 days after QUIN injection. This
pattern might reflect the acute characteristic of QUIN-
mediated lesion and the high sensitivity of FJ-C in acute
neuronal injury, in contrast to its low sensitivity in delayed
Figure 6 FJ-C positive cells after QUIN striatal injection (A–D). There was no difference in the striatal neurodegeneration of non-
transplanted (A) and transplanted (B) groups at day 1 after QUIN injection. However, a larger number of degenerating neurons was found
in saline-injected striata (C) compared to MSC-transplanted striata (D) 7 days after surgery. Graphs show quantification of FJ-C positive
cells in striata (E–F). In transplanted rats, we observed no differences in the number of FJ-C positive neurons at 1 d post-lesion (E), but 7 d
following surgery the striatal MSC transplantation significantly reduced the neurodegeneration (F) (*pb0.05, Student's t-test). Scale bar:
A–D=20 μm.
150 L. Moraes et al.assessment of damage (Lee et al., 2010). Because most cells
die in the first days after QUIN, we tested the neuroprotec-
tive potential of MSC transplanted early after the insult. The
first hours might be critical in saving damaged tissue, since
DNA fragmentation that indicates cellular death is detected
1 h after QUIN (Dure et al., 1995). It is possible that a similar
effect would be achieved if patients could be treated in the
initial phase of the disease.
We found significantly reduced striatal neurodegeneration
in lesioned rats 7 days after transplantation. This result may be
related to a paracrine effect of MSC, which might serve to
inhibit the progression of damage, as reviewed by others (Le
Blanc and Ringden, 2007; Uccelli et al., 2007). MSC are known
to release neurotrophic factors that are important for neuronal
survival and growth (Caplan and Dennis, 2006). Moreover,numerous reports have revealed that MSC have immunomod-
ulatory properties, including suppression of T-cell proliferation
(Aggarwal and Pittenger, 2005; Di Nicola et al., 2002),
inhibition of resting natural killer cytotoxic activity (Liu et
al., 2009; Sotiropoulou et al., 2006) and microglial activation
(Lee et al., 2009).
It is not known exactly when the improvements start after
MSC transplantation. We found no differences in the striatal
neurodegeneration of transplanted and non-transplanted
lesioned rats 24 h after the transplantation procedure. Thus,
a gap might be necessary between cell transplantation and
detectable neuroprotective effects. Since MSC-mediated
neuroprotection is related to their anti-inflammatory effects
and secretion of growth factors, 24 h may not be sufficient
for MSC to produce substantial amounts of soluble factors
Figure 7 Cell proliferation analysis in the SVZ. Micrographs show Ki-67+ cells in the SVZ of QUIN-treated (A), QUIN-untreated (B),
and unlesioned (C) rats. Quantitative analysis (D) showed that both treated and untreated animals had significantly enhanced SVZ
proliferation (*pb0.05) compared to unlesioned animals, but that transplantation per se did not affect SVZ proliferation (LV, lateral
ventricle) (*pb0.05, one-way ANOVA followed by Tukey's test). Scale bar: A–C=20 μm.
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further improvement. It is also possible that MSC transplan-
tation protected the partially integrated tissue and neurons
that undergo secondary death, but not neurons that die
rapidly after QUIN injection. Another potential explanation
for the absence of neuroprotection 24 h after QUIN lesion
might be that transplanted MSC act through interference with
a progressive inflammatory process that begins after the
initial damage. Our group has recently shown that cell therapy
has neuroprotective effects related to reduced microglial
activation in hypoxic–ischemic brain damage (Pimentel-
Coelho et al., 2010) and reduced astrogliosis after optic
nerve crush (Zaverucha-do-Valle et al., 2011). These data
corroborate the idea that stress signals in the lesioned tissue
can induce MSC to produce a more anti-inflammatory
phenotype (Ohtaki et al., 2008). Astrocytes and microglia
responses are characteristic in HD models and patients. It was
previously shown that in QUIN-lesioned rats, the density of
reactive astrogliosis corresponds to the local severity of the
neurodegenerative process (Guncova et al., 2011) and in HD
patients the microglial activation correlates with severity
(Pavese et al., 2006). Thus, the inflammatory processes after
MSC transplantation in HD models remain an important issue
for further investigation.In HD, the cerebral tissue loss is compensated by the
enhancement of the ventricular area, and ventriculomegaly
is indicative of a progressive neurodegeneration (Guncova
et al., 2011). We found reduced ventriculomegaly 9 months
after QUIN injection and MSC transplantation. This finding is
in accordance with the previous data that late transplanta-
tion of MSC leads to reversal of striatal atrophy (Amin et al.,
2008), and suggests that the neuroprotective effects of MSC
are not transitory. The observed neuroprotective effect of
MSC transplantation is also in accordance with previous
evidences that bone marrow stem cell transplantation leads
to improved motor skills in animal models of HD (Edalatmanesh
et al., 2010; Jiang et al., 2011; Lescaudron et al., 2003).
We observed a discrete enhancement of FGF-2, but not
BDNF striatal expression 7 days after lesion in treated rats.
FGF-2 is expressed constitutively in the brain (Baird and
Walicke, 1989), and can be secreted by cells of the damaged
tissue (Reuss and von Bohlen und Halbach, 2003). FGF-2 is
neuroprotective in many neurological diseases (Reuss and
von Bohlen und Halbach, 2003) and after ischemia it
prevents neuronal death in a dose-dependent manner
(Nakata et al., 1993). It is known that FGF-2 can reduce
cellular death in striatal cultures of the R6/2 transgenic





Figure 8 Ventriculomegaly analysis to assess striatal shrinkage.
Photomontage of brain coronal sections illustrates an unlesioned
brain (A) and the pronounced enlargement of lateral ventricles in
untreated (B) rats compared to MSC transplanted animals (C),
9 months after lesion. The dashed lines delineate the ventricular
area and the arrow indicates the brain midline (A–C). Graph shows
measurements of the ventricular area in coronal sections of
different brain rostrocaudal levels (D). Ventriculomegaly is signif-
icantly less severe in themedial region of treated animals compared
to the untreated group (*pb0.05, one-way ANOVA followed by
Tukey's test). 1.
152 L. Moraes et al.of this factor leads to functional improvements in R6/2 mice
(K. Jin et al., 2005). Our group has previously shown that
bone-marrow mononuclear cells can increase neuroprotec-
tion, neuroregeneration, and FGF-2 expression in a model of
optic nerve crush (Zaverucha-do-Valle et al., 2011). Thus, it
is possible that the neuroprotection after QUIN injection is,
at least in part, mediated by FGF-2 secreted by transplanted
MSC, but it is unlikely that this is the only factor to play a role.
FGF-2 activates a range of signal transduction pathways,
among which the phosphatidylinositol 3′-kinase/Akt pathway
is related to cell survival (K. Jin et al., 2005).
We observed a considerable and significant enhancement
in SVZ cell proliferation after QUIN injection, in both
transplanted and non-transplanted rats. Many investigators
have described enhanced proliferation and/or altered SVZ
migration in response to brain lesions, including HD (Curtis
et al., 2003; Moraes et al., 2009), ischemia (Liu et al., 1998),
Alzheimer's (K. Jin et al., 2004) and Parkinson's (Zhao et al.,
2003) diseases (Batista et al., 2006; Goings et al., 2004),
giving rise to the possibility of cell replacement from
endogenous precursors (Arvidsson et al., 2002). The ob-
served proliferative response in the SVZ of QUIN-lesioned
rats was previously correlated with stem cell-factor release
from the lesioned striata, which activates the c-kit receptor
in neural stem cells and a signaling pathway associated with
cellular proliferation and migration (Bantubungi et al.,
2008). Although we did not find proliferative modulation
associated with MSC transplantation in the SVZ, our analysis
was time-limited, and we do not reject the hypothesis that
MSC can affect the SVZ microenvironment. One possibility is
that the newly generated cells in the SVZ survive longer
after MSC transplantation. In accordance with this view,
previous findings showed that MSC can enhance neuroblast
proliferation and differentiation in the striata of R6/2 mice
(Lin et al., 2011). Indeed, we observed Ki-67-positive cells in
the striata of both transplanted and non-transplanted QUIN-
lesioned rats (data not shown) and it is possible that some of
these cells were neuroblasts.
Previous studies demonstrated SPION-labeling in a variety
of human (Niemeyer et al., 2010; Song et al., 2007) and animal
(Rice et al., 2007; Zhu et al., 2007) stem cells. We used SPION
to track MSC in the QUIN model. SPION were internalized in
MSC without affecting cellular viability. These data corrobo-
rate previous findings of SPION biosafety (Arbab et al., 2003)
and viability maintenance 3 to 7 days after labeling, even
using high concentrations of SPION (Jasmin et al., 2010). The
MRI signal was generated by labeled cells and remained
restricted to the injection site 1 h after transplantation. MRI
signals lasted for at least 60 days, and it is likely that it
gradually disappeared due to cell proliferation. Previous data
showed that inhibition of cell proliferation mediated by
Mitomycin-C reduces SPION loss from labeled MSC (Jasmin et
al., 2010).
Our in vivo tracking of SPION-labeled MSC suggested
migration from the injection site to the contralateral lesioned
striatum. MSC migration between hemispheres was described
earlier (Li et al., 2011;Wang et al., 2002). Because stained cells
were located next to blood vessels and cerebral ventricles, we
speculate that they migrated through the blood flow and/or
the liquor. MSC migration has been associated with SDF-1/
CXCR4 pathway (Tyndall et al., 2007), fractalcin and its
receptor CX3CR1 (Ji et al., 2004) (Sordi et al., 2005), TNF-α,
Figure 9 Analysis of BDNF and FGF2 expression levels. The normal striata express both neurotrophic factors. In both treated and
untreated lesioned animals, BDNF expression seems to increase in relation to unlesioned animals, but the difference is not significant
between the groups. In the MSC-treated group, the level of FGF-2 expression is significantly more pronounced than in the saline group
when both are compared to unlesioned animals (*pb0.05, one-way ANOVA followed by Tukey's test).
153Neuroprotective effects and MRI of mesenchymal stem cells in a rat model of Huntington's diseaseand MCP-1 (Fu et al., 2009). MSC local permanence seems not
to require persistent integration. The “touch and go effect”
(Uccelli et al., 2008) has been discussed as a potential
therapeutic characteristic of MSC, which includes induction
of a neuroprotective microenvironment with subsequent
clearance of the lesioned tissue.
In the present study, we showed that acute MSC transplan-
tation can produce long-term benefits in the QUIN model of
HD, and it is possible that neuroprotection occurs in other
neurological diseases in which excitotoxicity plays a role.
Further in vivo monitoring of transplanted cells will be
instrumental for a better understanding of their migratory
dynamics and to improve clinical transplantation strategies.Acknowledgments
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